ANI PHARMACEUTICALS INC
ANIPNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $883.4M | $614.4M | $486.8M | $316.4M | $216.1M | $208.5M |
| Operating income | $111.1M | $584,000 | $47.0M | −$35.3M | −$39.8M | −$16.0M |
| Net income | $78.3M | −$18.5M | $18.8M | −$47.9M | −$42.6M | −$22.5M |
| Total assets | $1.44B | $1.28B | $904.4M | $760.1M | $771.6M | $461.2M |
| Total liabilities | $899.7M | $855.9M | $446.8M | $421.5M | $412.9M | $265.5M |
| Equity | $540.7M | $403.7M | $432.7M | $313.7M | $333.9M | $195.7M |
| EPS (diluted) | $3.32 | $-1.04 | $0.85 | $-3.05 | $-3.40 | $-1.88 |
| Shares out. | 22.5M | 21.1M | 18.2M | 16.3M | 12.6M | 12.0M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 12.6%
- Net margin
- 8.9%
- Return on equity
- 14.5%
- Return on assets
- 5.4%
- Return on capital (ROCE)
- 9.6%
- Liabilities / assets
- 62.5%
- Debt / equity
- 1.66×
- Book value / share
- $24.04
- Revenue growth (YoY)
- 43.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 3.26safe
- Accruals / assets
- −7.4%clean
- Piotroski F-Score
- 7/9strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 5 good- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Group IncPassive (13G)Mar 26, 2026
- Integrated Core Strategies (Us) LlcPassive (13G)Nov 13, 2025
- Blackrock, Inc.Passive (13G)Oct 17, 2025
- Meridian Venture Partners Ii Gp, L.P.Activist (13D)Aug 22, 2025
- Millennium Management LlcPassive (13G)Apr 10, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Walsh Patrick DDirector | May 11, 2026 | Sell | 3,973 | $80.75 |
| Rowland Thomas AndrewOfficer — SVP, HEAD - ESTABLISHED BRANDS | May 12, 2026 | Sell | 459 | $79.21 |
| Lalwani NikhilOfficer — PRESIDENT & CEO | May 11, 2026 | Sell | 55,000 | $77.57 |
| Gutwerg OriOfficer — SVP, GENERICS | May 12, 2026 | Sell | 2,772 | $79.50 |
| Cook MeredithOfficer — SR. VP, GENERAL COUNSEL & SEC. | May 13, 2026 | Sell | 500 | $78.16 |
| Cook MeredithOfficer — SR. VP, GENERAL COUNSEL & SEC. | Apr 13, 2026 | Sell | 500 | $77.95 |
| Rowland Thomas AndrewOfficer — SVP, HEAD - ESTABLISHED BRANDS | Mar 11, 2026 | Sell | 4,772 | $74.91 |
| Mutz ChristopherOfficer — HEAD OF RARE DISEASE | Mar 13, 2026 | Sell | 3,162 | $71.64 |
| Cook MeredithOfficer — SR. VP, GENERAL COUNSEL & SEC. | Mar 13, 2026 | Sell | 500 | $72.62 |
| Mutz ChristopherOfficer — HEAD OF RARE DISEASE | Mar 6, 2026 | Sell | 2,121 | $74.22 |
| Lalwani NikhilOfficer — PRESIDENT & CEO | Mar 7, 2026 | Tax withholding | 17,060 | $74.04 |
| Gutwerg OriOfficer — SVP, GENERICS | Mar 7, 2026 | Tax withholding | 3,314 | $74.04 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.6M | 7.7 | +1.7% |
| Apr 30, 2026 | 3.6M | 13.0 | +2.0% |
| Apr 15, 2026 | 3.5M | 8.8 | -2.6% |
| Mar 31, 2026 | 3.6M | 12.0 | -0.5% |
| Mar 13, 2026 | 3.6M | 7.9 | +2.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Shareholder voteMay 21, 2026
- Regulation FD disclosureMay 13, 2026
- Results of operationsMay 8, 2026
- Changed auditorApr 7, 2026
- Regulation FD disclosureMar 3, 2026
- Results of operationsFeb 27, 2026
- Results of operations · Regulation FD disclosureJan 12, 2026
- Director / officer change · Regulation FD disclosureDec 1, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.